A23V2200/328

COMPOSITION COMPRISING ISOMERS OF INOSITOL AND ITS USE

A combination of scyllo-inositol and myo-inositol, wherein, the scyllo-inositol and myo-inositol are nutritional ingredients for use in the prevention or treatment of a condition selected from the group consisting of prediabetes, type II diabetes, gestational diabetes mellitus and a condition associated with any of the forgoing in a subject, and a composition comprising scyllo-inositol and myo-inositol.

LOW GLYCEMIC GUMMY COMPOSITION AND METHODS OF MAKING AND USING THEREOF
20210228483 · 2021-07-29 ·

A low glycemic gummy composition is provided. The gummy composition includes a gelling component in a sufficient amount to provide a cohesive gelled product, and a low glycemic index sugar component having a glycemic index of not more than 20. The gummy composition includes not less than 50% weight of the low glycemic index sugar component. In some embodiments, the gummy composition further includes an active component, wherein the active component comprises a vitamin composition, a mineral composition, an amino acid composition, an antioxidant composition, an herbal composition, or an active pharmaceutical ingredient (API) composition. The gummy composition may be substantially free of D-glucose, D-fructose, and sugar substitutes such as non-sugar sweeteners and sugar alcohols.

LOW GLYCEMIC GUMMY COMPOSITION AND METHODS OF MAKING AND USING THEREOF
20210228483 · 2021-07-29 ·

A low glycemic gummy composition is provided. The gummy composition includes a gelling component in a sufficient amount to provide a cohesive gelled product, and a low glycemic index sugar component having a glycemic index of not more than 20. The gummy composition includes not less than 50% weight of the low glycemic index sugar component. In some embodiments, the gummy composition further includes an active component, wherein the active component comprises a vitamin composition, a mineral composition, an amino acid composition, an antioxidant composition, an herbal composition, or an active pharmaceutical ingredient (API) composition. The gummy composition may be substantially free of D-glucose, D-fructose, and sugar substitutes such as non-sugar sweeteners and sugar alcohols.

METHODS OF MAKING FOOD ADDITIVES FROM BANANA PLANT STEM
20210169963 · 2021-06-10 ·

Described herein are food additives prepared from the inner core of a banana plant stem, along with methods of making and using same.

METHODS OF MAKING FOOD ADDITIVES FROM BANANA PLANT STEM
20210169963 · 2021-06-10 ·

Described herein are food additives prepared from the inner core of a banana plant stem, along with methods of making and using same.

COMPOSITIONS COMPRISING 3'-O-METHYL-4'-O-SULFATE EPICATECHIN AND THERAPEUTIC USES OF SUCH COMPOSITIONS

Compositions can comprise the catechin metabolite 3′-O-methyl-4′-O-sulfate epicatechin. In some embodiments, the composition can be used in a method for blood vessel dilation and/or increased delivery of blood flow to tissues in the body, for example by administering the composition to an individual having or at risk of high blood pressure or a cardiovascular disease. In some embodiments, the compositions are used for weight maintenance or weight loss. In further embodiments the compositions are used for treating or preventing gestational diabetes mellitus. The compositions may be administered orally as a food product in which the 3′-O-methyl-4′-O-sulfate epicatechinis present in a concentration of at least 0.01 mg/g of the food product.

COMPOSITIONS COMPRISING 3'-O-METHYL-4'-O-SULFATE EPICATECHIN AND THERAPEUTIC USES OF SUCH COMPOSITIONS

Compositions can comprise the catechin metabolite 3′-O-methyl-4′-O-sulfate epicatechin. In some embodiments, the composition can be used in a method for blood vessel dilation and/or increased delivery of blood flow to tissues in the body, for example by administering the composition to an individual having or at risk of high blood pressure or a cardiovascular disease. In some embodiments, the compositions are used for weight maintenance or weight loss. In further embodiments the compositions are used for treating or preventing gestational diabetes mellitus. The compositions may be administered orally as a food product in which the 3′-O-methyl-4′-O-sulfate epicatechinis present in a concentration of at least 0.01 mg/g of the food product.

SYNERGISTIC NUTRITIONAL COMPOSITIONS FOR ENHANCING ATP EFFICIENCY

The invention disclosed herein relates to synergistic nutritional compositions for enhancing cellular ATP efficiency. Particularly, the invention relates to a synergistic, efficient, nutritional composition for promoting cellular ATP production comprising a therapeutically active exogenous combination of a stabilized oxaloacetate and a biotin-manganese complex along with pharmaceutically acceptable excipients; wherein the stabilized oxaloacetate and the biotin-manganese or salts thereof are present in a weight ratio ranging from 1:0.01 to 1:0.2. Further, the present synergistic nutritional composition is useful for treating ATP deficiency disorders, age-related metabolic disorders, neurodegenerative diseases, cardiovascular diseases, bone related disorders, central nervous system diseases, cognitive disorders and like thereof.

SYNERGISTIC NUTRITIONAL COMPOSITIONS FOR ENHANCING ATP EFFICIENCY

The invention disclosed herein relates to synergistic nutritional compositions for enhancing cellular ATP efficiency. Particularly, the invention relates to a synergistic, efficient, nutritional composition for promoting cellular ATP production comprising a therapeutically active exogenous combination of a stabilized oxaloacetate and a biotin-manganese complex along with pharmaceutically acceptable excipients; wherein the stabilized oxaloacetate and the biotin-manganese or salts thereof are present in a weight ratio ranging from 1:0.01 to 1:0.2. Further, the present synergistic nutritional composition is useful for treating ATP deficiency disorders, age-related metabolic disorders, neurodegenerative diseases, cardiovascular diseases, bone related disorders, central nervous system diseases, cognitive disorders and like thereof.

FASTING CONDITION AS DIETARY TREATMENT OF DIABETES
20210145038 · 2021-05-20 ·

A method of alleviating symptoms of, or treating, pancreatic beta-cell damage in a subject includes a step of identifying a subject having pancreatic beta-cell damage. Multiple cycles of a diet protocol are administered to the subject. The diet protocol includes administering of a fasting mimicking diet and a re-feeding diet where the fasting mimicking diet is provided for a first time period and the re-feeding diet is provided for a second time period.